A trial looking at ABR-217620 for advanced lung, pancreatic and kidney cancer

Overview

Cancer types:

Kidney cancer, Lung cancer, Non small cell lung cancer (NSCLC), Pancreatic cancer, Renal cell cancer

Status:

Results

Phase:

Phase 1

Details

This trial looked at ABR-217620 for people with advanced non small cell lung cancer (NSCLC), pancreatic cancer or kidney cancer (renal cell cancer).

Doctors usually treat cancer with surgery, chemotherapy or radiotherapy. But sometimes it can start to grow again or spread to another part of the body. If this happens it is often more difficult to treat.

Some types of cancer cells have a protein called 5T4 on the surface. Researchers think that this protein may be involved when cancer cells spread (metastasise) to another part of the body.

ABR-217620 (naptumomab estafenatox) is a type of biological therapy. It is a combination of two proteins. The theory is that one protein attaches to cancer cells that have 5T4 on their surface. And the other protein activates the immune system so that it recognises and kills these cancer cells.

Recruitment start: 1 April 2003

Recruitment end: 30 November 2006